| Patents for A61P 35 - Antineoplastic agents (221,099) |
|---|
| 01/14/2014 | US8629248 Glycosylation engineering of antibodies for improving antibody-dependent cellular cytotoxicity |
| 01/14/2014 | US8629241 Alpha helical mimics, their uses and methods for their production |
| 01/14/2014 | US8629240 Peptide ligands for clusterin and uses thereof |
| 01/14/2014 | US8629142 Modulators of toll-like receptors |
| 01/14/2014 | US8629136 Bisfluoroalkyl-1,4-benzodiazepinone compounds |
| 01/14/2014 | US8629117 Method for stimulating the immune system |
| 01/14/2014 | US8629107 Genes and proteins associated with angiogenesis and uses thereof |
| 01/14/2014 | US8629096 Compositions comprising fungal immunomodulatory protein and use thereof |
| 01/14/2014 | US8628784 Adjuvant systems and vaccines |
| 01/14/2014 | US8628775 Methods of reducing T cell-mediated immune responses with multimeric P-selectin and/or E-selectin compounds |
| 01/14/2014 | CA2747055C Substituted benzimidazole derivatives as protein kinase inhibitors |
| 01/14/2014 | CA2746423C Aminopyrazole compounds as chki inhibitors |
| 01/14/2014 | CA2721692C Triazine compounds as p13 kinase and mtor inhibitors |
| 01/14/2014 | CA2713673C Agent for enhancing anti-tumor effect comprising oxaliplatin liposome preparation, and anti-tumor agent comprising the liposome preparation |
| 01/14/2014 | CA2561073C Composition and method for cancer treatment |
| 01/14/2014 | CA2519875C Method of tumor regression with vegf inhibitors |
| 01/14/2014 | CA2370252C Cancer treatment with endothelin receptor antagonists |
| 01/09/2014 | WO2014008407A1 Therapeutic bisphosphonates |
| 01/09/2014 | WO2014008385A1 Compositions and methods useful for making orthotopic tumors with controllable metastasis |
| 01/09/2014 | WO2014008270A1 Solid state form of vemurafenib choline salt |
| 01/09/2014 | WO2014008248A2 Compositions and methods for treating and inhibiting viral infections |
| 01/09/2014 | WO2014008197A1 Heterocyclic modulators of lipid synthesis |
| 01/09/2014 | WO2014008159A1 Selective estrogen receptor degraders for treatment of tamoxifen resistant tumors |
| 01/09/2014 | WO2014007669A1 Autologous cell vaccine for treating oncological diseases and method for producing same |
| 01/09/2014 | WO2014007513A1 Novel monoclonal antibody binding specifically to dll4 and use thereof |
| 01/09/2014 | WO2014007447A1 Composition for preventing or treating diseases caused by angiogenesis, containing hydroxychalcone compound as active ingredient |
| 01/09/2014 | WO2014007438A1 Aptamer for periostin and anti-cancer composition including same |
| 01/09/2014 | WO2014007412A1 Novel compound or pharmaceutically acceptable salt thereof, and pharmaceutical composition containing same as active ingredient |
| 01/09/2014 | WO2014007398A1 Cationic lipid |
| 01/09/2014 | WO2014007369A1 Fgfr2 fusion gene |
| 01/09/2014 | WO2014007303A1 Therapeutic method and remedy for htlv-1-associated myelopathy patients |
| 01/09/2014 | WO2014007266A1 Transdermal cancer antigen peptide preparation |
| 01/09/2014 | WO2014007217A1 Antitumor effect potentiator composed of imidazooxazine compound |
| 01/09/2014 | WO2014006625A1 Pharmaceutical composition comprising amino-phenyl- acetic acid octadec-(z)-9-enyl ester and use thereof for treating tumors |
| 01/09/2014 | WO2014006572A1 Selective pi3k delta inhibitors |
| 01/09/2014 | WO2014006554A1 3-(PYRAZOLYL)-1H-PYRROLO[2,3-b]PYRIDINE DERIVATIVES AS KINASE INHIBITORS |
| 01/09/2014 | WO2014006349A1 Lipiodol-based anti-tumour emulsion for treating cancer |
| 01/09/2014 | WO2014006217A1 Dimeric protein with triple mutations |
| 01/09/2014 | WO2014006115A1 Combination of a phosphoinositide 3-kinase inhibitor and an inhibitor of the il-8/cxcr interaction |
| 01/09/2014 | WO2014006113A1 Method of treating cancer by effective amounts of aflibercept |
| 01/09/2014 | WO2014006020A1 Gpbp-1 inhibition and its therapeutic use |
| 01/09/2014 | WO2014005513A1 Cyclopeptide lhrh antagonist derivatives and pharmacal use thereof |
| 01/09/2014 | WO2014005408A1 Antibiotic tetrathiazomycin a and preparation method thereof and use in preparation of antitumour drug |
| 01/09/2014 | WO2014005182A1 Phosphoinositide 3-kinase (pi3k) inhibitors |
| 01/09/2014 | WO2013142873A3 Complex and structurally diverse compounds |
| 01/09/2014 | WO2013124026A8 8 - substituted 2 -amino - [1,2,4] triazolo [1, 5 -a] pyrazines as syk tryrosine kinase inhibitors and gcn2 serin kinase inhibitors |
| 01/09/2014 | US20140011858 Inhibitor of IRS-1 for Treating Skin Disorders |
| 01/09/2014 | US20140011844 Migrastatin analogs and uses thereof |
| 01/09/2014 | US20140011837 Compositions and methods for treating warts associated with viral infections |
| 01/09/2014 | US20140011754 Crystalline form of benzylbenzene sglt2 inhibitor |
| 01/09/2014 | US20140011215 Measuring circulating therapeutic antibody, antigen and antigen/antibody complexes using elisa assays |
| 01/09/2014 | US20140010892 Benzimidazole derivatives and their use as protein kinase inhibitors |
| 01/09/2014 | US20140010825 Diagnostic and therapeutic potential of HLA-E monospecific monoclonal IgG antibodies directed against tumor cell surface and soluble HLA-E |
| 01/09/2014 | US20140010798 Albumin fusion proteins |
| 01/09/2014 | US20140010780 Vaccine immunotherapy for immune suppressed patients |
| 01/09/2014 | US20140010779 Vaccine immunotherapy for immune suppressed patients |
| 01/09/2014 | CA2878413A1 Therapeutic bisphosphonates |
| 01/09/2014 | CA2877999A1 Heterocyclic modulators of lipid synthesis |
| 01/09/2014 | CA2877848A1 Therapeutic method and medicament for htlv-1 associated myelopathy (ham) |
| 01/09/2014 | CA2876995A1 Selective pi3k delta inhibitors |
| 01/09/2014 | CA2876689A1 Substituted tricyclic compounds as fgfr inhibitors |
| 01/08/2014 | EP2682475A1 Antibody and antigen recognizing tumor-initiating cells and use thereof |
| 01/08/2014 | EP2682468A2 Gene silencing of the brother of the regulator of imprinted sites (BORIS) |
| 01/08/2014 | EP2682459A1 Oncolytic adenovirus for target therapy of human tumor and use thereof |
| 01/08/2014 | EP2682405A1 Tumor necrosis factor- humanized antibody |
| 01/08/2014 | EP2682397A1 Prodrugs of phosphonate nucleotide analogues and methods for selecting and making same |
| 01/08/2014 | EP2682389A1 Dihydropyrimidin-2(1H)-ones and dihydropyrimidin-2(1H)-thiones as inhibitors of sodium iodide symporter |
| 01/08/2014 | EP2682386A1 Novel vitamin d receptor modulator with partial agonist activity |
| 01/08/2014 | EP2682384A1 Auto-magnetic metal salen complex compound |
| 01/08/2014 | EP2682128A1 Medicinal agent for inhibiting metastasis of malignant tumor |
| 01/08/2014 | EP2681243A2 Anti-il-6 receptor antibodies and methods of use |
| 01/08/2014 | EP2681227A1 Phosphoramidate derivatives of 5 - fluoro - 2 ' - deoxyuridine for use in the treatment of cancer |
| 01/08/2014 | EP2681221A1 Tricyclic inhibitors of kinases |
| 01/08/2014 | EP2681216A2 Substituted 6,5-fused bicyclic heteroaryl compounds |
| 01/08/2014 | EP2681215A1 Serine/threonine kinase inhibitors |
| 01/08/2014 | EP2681207A2 Heterocyclic compounds for the inhibition of pask |
| 01/08/2014 | EP2681203A1 NOVEL ESTERS OF 4,9-DIHYDROXY-NAPHTHO[2,3-b]FURANS FOR DISEASE THERAPIES |
| 01/08/2014 | EP2681197A1 Tetrasubstituted cyclohexyl compounds as kinase inhibitors |
| 01/08/2014 | EP2681195A1 Novel kinase inhibitors |
| 01/08/2014 | EP2681193A1 Pharmaceutically active disubstituted pyridine derivatives |
| 01/08/2014 | EP2680925A1 Interrogatory cell-based assays and uses thereof |
| 01/08/2014 | EP2680919A2 Immunologically modified carbon nanotubes for cancer treatment |
| 01/08/2014 | EP2680887A1 Dipyridinium derivatives |
| 01/08/2014 | EP2680882A1 Therapeutic cancer vaccine |
| 01/08/2014 | EP2680854A1 Method for administration of a gamma secretase inhibitor |
| 01/08/2014 | EP2680853A1 Treatment of cancer with dopamine receptor antagonists |
| 01/08/2014 | EP2680847A1 Pyrimidine compounds inhibiting the formation of nitric oxide and prostaglandin e2, method of production thereof and use thereof |
| 01/08/2014 | EP2680839A1 Co -administration of eribulin and farletuzumab for the treatment of breast cancer |
| 01/08/2014 | EP2680813A1 Diethylstilbestrol dosage form and use for the treatment of prostate or breast cancer |
| 01/08/2014 | EP2468771A9 Pharmaceutical composition containing anti-hb-egf antibody as active ingredient |
| 01/08/2014 | CN103502453A Compositions and methods for treating, diagnosing and monitoring disease |
| 01/08/2014 | CN103502438A Method and compositions for cellular immunotherapy |
| 01/08/2014 | CN103502319A Pharmaceutical composition containing block copolymer comprising boric acid compound |
| 01/08/2014 | CN103502274A Anti-il-6 receptor antibodies and methods of use |
| 01/08/2014 | CN103502248A Pyrazolo pyrimidine derivatives |
| 01/08/2014 | CN103502247A 7-azaindole derivatives |
| 01/08/2014 | CN103502241A Substituted pyrimidinyl-pyrroles active as kinase inhibitors |
| 01/08/2014 | CN103502227A 1,3 oxazines as bace1 and/or bace2 inhibitors |
| 01/08/2014 | CN103501859A Interrogatory cell-based assays and uses thereof |
| 01/08/2014 | CN103501824A Enhanced therapeutic usage of a purine nucleoside phosphorylase or nucleoside hydrolase prodrug related applications |